{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:58:17Z","timestamp":1788872297629,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"The Netherlands Organization of Scientific Research-Medical Sciences","award":["PGN 902-17-090"],"award-info":[{"award-number":["PGN 902-17-090"]}]},{"name":"Dutch Cancer Foundation Koningin Wilhelmina Fonds","award":["RUL2000-2196"],"award-info":[{"award-number":["RUL2000-2196"]}]},{"name":"Dutch Cancer Foundation Koningin Wilhelmina Fonds","award":["UL2007-3801"],"award-info":[{"award-number":["UL2007-3801"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.bbrc.2009.11.097","type":"journal-article","created":{"date-parts":[[2009,12,15]],"date-time":"2009-12-15T04:29:12Z","timestamp":1260851352000},"page":"1161-1165","source":"Crossref","is-referenced-by-count":5,"title":["An in vitro model that can distinguish between effects on angiogenesis and on established vasculature: Actions of TNP-470, marimastat and the tubulin-binding agent Ang-510"],"prefix":"10.1016","volume":"391","author":[{"given":"Jens","family":"van Wijngaarden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.A.","family":"Snoeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ermond","family":"van Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henny","family":"Bloys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Kaijzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor W.M.","family":"van Hinsbergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens W.G.M.","family":"L\u00f6wik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2009.11.097_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2009.11.097_bib2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0092-8674(00)80108-7","article-title":"Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis","volume":"86","author":"Hanahan","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2009.11.097_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1259\/0007-1285-66-783-181","article-title":"Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy","volume":"66","author":"Denekamp","year":"1993","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.bbrc.2009.11.097_bib4","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJM199512283332608","article-title":"Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis","volume":"333","author":"Folkman","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2009.11.097_bib5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0093-7754(01)90287-8","article-title":"Overview of angiogenesis: biologic implications for antiangiogenic therapy","volume":"28","author":"Ellis","year":"2001","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bbrc.2009.11.097_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0167-8140(00)00243-7","article-title":"Targeting tumor blood vessels: an adjuvant strategy for radiation therapy","volume":"57","author":"Siemann","year":"2000","journal-title":"Radiother. Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.bbrc.2009.11.097_bib7","first-page":"57","article-title":"Tumour vasculature as a target for cancer therapy","volume":"80","author":"Chaplin","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2009.11.097_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF00046365","article-title":"Vascular attack as a therapeutic strategy for cancer","volume":"9","author":"Denekamp","year":"1990","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bbrc.2009.11.097_bib9","first-page":"4","article-title":"Vascular targeting agents Horizons","volume":"3","author":"Siemann","year":"2002","journal-title":"Cancer Ther."},{"key":"10.1016\/j.bbrc.2009.11.097_bib10","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clon.2004.11.011","article-title":"Vascular disrupting agents: a new class of drug in cancer therapy","volume":"17","author":"Gaya","year":"2005","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"10.1016\/j.bbrc.2009.11.097_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1628","article-title":"Disrupting tumour blood vessels","volume":"5","author":"Tozer","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2009.11.097_bib12","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1002\/jcb.20783","article-title":"Vascular disrupting agents","volume":"99","author":"Pilat","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.bbrc.2009.11.097_bib13","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1002\/cncr.20299","article-title":"Vascular-targeting therapies for treatment of malignant disease","volume":"100","author":"Siemann","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2009.11.097_bib14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1158\/1078-0432.CCR-0642-03","article-title":"Vascular targeting agents as cancer therapeutics","volume":"10","author":"Thorpe","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2009.11.097_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2174\/157489207779561462","article-title":"Small molecule vascular disrupting agents: potential new drugs for cancer treatment","volume":"2","author":"Cai","year":"2007","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.bbrc.2009.11.097_bib16","first-page":"522","article-title":"Current development status of small-molecule vascular disrupting agents","volume":"7","author":"Chaplin","year":"2006","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.bbrc.2009.11.097_bib17","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/sj.bjc.6603694","article-title":"Vascular disrupting agents in clinical development","volume":"96","author":"Hinnen","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2009.11.097_bib18","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.clon.2007.03.014","article-title":"Vascular damaging agents","volume":"19","author":"Patterson","year":"2007","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"issue":"Spec No. 1","key":"10.1016\/j.bbrc.2009.11.097_bib19","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1259\/bjr\/36205483","article-title":"Tumour vascular disrupting agents: combating treatment resistance","volume":"81","author":"Tozer","year":"2008","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.bbrc.2009.11.097_bib20","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.ijrobp.2004.08.002","article-title":"Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors","volume":"60","author":"Siemann","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bbrc.2009.11.097_bib21","first-page":"2027","article-title":"Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503)","volume":"28","author":"Siemann","year":"2008","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2009.11.097_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00441-008-0646-0","article-title":"Vascular targeted therapies in oncology","volume":"335","author":"Siemann","year":"2009","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.bbrc.2009.11.097_bib23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/labinvest.3780207","article-title":"Effect of angiogenic and antiangiogenic compounds on the outgrowth of capillary structures from fetal mouse bone explants","volume":"81","author":"Deckers","year":"2001","journal-title":"Lab. Invest."},{"key":"10.1016\/j.bbrc.2009.11.097_bib24","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1023\/A:1023889805133","article-title":"The role of the matrix metalloproteinases during in vitro vessel formation","volume":"5","author":"Burbridge","year":"2002","journal-title":"Angiogenesis"},{"key":"10.1016\/j.bbrc.2009.11.097_bib25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1600-0463.2006.apm_189.x","article-title":"Influence of angiogenesis inhibitors on endothelial cell morphology in vitro","volume":"114","author":"Friis","year":"2006","journal-title":"APMIS"},{"key":"10.1016\/j.bbrc.2009.11.097_bib26","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bcp.2004.05.020","article-title":"Participation of cyclin D1 deregulation in TNP-470-mediated cytostatic effect: involvement of senescence","volume":"68","author":"Lien","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2009.11.097_bib27","doi-asserted-by":"crossref","first-page":"12782","DOI":"10.1073\/pnas.97.23.12782","article-title":"The antiangiogenic agent TNP-470 requires p53 and p21CIP\/WAF for endothelial cell growth arrest","volume":"97","author":"Yeh","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2009.11.097_bib28","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.1073\/pnas.97.12.6427","article-title":"Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1\/CIP1","volume":"97","author":"Zhang","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2009.11.097_bib29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1582-4934.2005.tb00355.x","article-title":"Matrix metalloproteinases and angiogenesis","volume":"9","author":"Rundhaug","year":"2005","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bbrc.2009.11.097_bib30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/jnci\/87.4.293","article-title":"Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases","volume":"87","author":"Taraboletti","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.bbrc.2009.11.097_bib31","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/bjc.1994.41","article-title":"Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470)","volume":"69","author":"Kusaka","year":"1994","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbrc.2009.11.097_bib32","first-page":"4510","article-title":"Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4","volume":"58","author":"Iyer","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2009.11.097_bib33","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/labinvest.3780060","article-title":"Regulation of vascular growth and regression by matrix metalloproteinases in the rat aorta model of angiogenesis","volume":"80","author":"Zhu","year":"2000","journal-title":"Lab. Invest."},{"key":"10.1016\/j.bbrc.2009.11.097_bib34","first-page":"189","article-title":"Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate","volume":"19","author":"Chaplin","year":"1999","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2009.11.097_bib35","first-page":"93","article-title":"Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo","volume":"21","author":"Galbraith","year":"2001","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2009.11.097_bib36","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/sj.bjc.6692174","article-title":"In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug","volume":"81","author":"Grosios","year":"1999","journal-title":"Br. J. Cancer"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X09022748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X09022748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T12:53:22Z","timestamp":1544792002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X09022748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0006291X09022748"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2009.11.097","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}